Compare YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax Magnificent 7 Fund of Option Income ETFs vs Zimmer Biomet Holdings Inc — how do they compare? YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.2, while Zimmer Biomet Holdings Inc trades at $94.73 (market cap $17.97B). The key difference: Zimmer Biomet Holdings Inc pays a 1.02% dividend while YieldMax Magnificent 7 Fund of Option Income ETFs pays none, and Zimmer Biomet Holdings Inc is trading nearer its 52-week high, YieldMax Magnificent 7 Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| YMAG | ZBH | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $15.98 | $104.26 |
52-Week Low | $10.76 | $79.58 |
Market Cap | — | $17.97B |
Enterprise Value | — | $25.04B |
Dividend Yield | — | 1.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
YMAG trades at $11.26, down slightly (-0.18%) on the day. The technical outlook is bullish with moving averages supporting upward momentum, though oscillators remain neutral. The ETF maintains a consistent weekly dividend distribution strategy, with recent payouts ranging from $0.07 to $0.11 per share. Recent news highlights YieldMax's ongoing distribution announcements and trading activity, with the stock showing 2.7% gains in recent sessions according to Defense World (August 4, 2026).
The outlook remains positive given the bullish technical signals and consistent income generation through dividends. However, investors should monitor NAV stability during earnings periods as noted by Seeking Alpha (July 28, 2026). Key risks include option strategy execution and market volatility affecting the underlying Magnificent 7 components. The ETF's performance remains tied to successful option income generation and component stock stability.
Zimmer Biomet (ZBH) trades at $94.22, down 3.93% on the day, with a bearish technical signal but strong fundamentals including a 69.87% gross margin and three consecutive quarterly earnings beats. Revenue growth is steady, reaching $8.23B in 2025, though net income margin dipped to 8.56%. Recent leadership promotions aim to accelerate commercial transformation, while analyst consensus price target is $104.88, implying 11.3% upside.
The stock presents a value opportunity with a P/E of 22.87 and P/S of 2.17, supported by robust cash flow and dividend payments. Risks include rising debt-to-asset ratio (32.57% in 2025) and competitive pressures. Wall Street sentiment is mixed with 40.48% buy ratings, but technical indicators suggest near-term caution amid bearish moving averages.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
